Floatz logo

Cetuximab

Salivary Gland Adenoid Cystic Carcinoma

Fox Chase Cancer Centermonoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Salivary Gland Adenoid Cystic Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 1/2B
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC
Everolimus
Fox Chase Cancer Center
Phase 1CC
Recombinant Interleukin-12
National Cancer Institute (NCI)
Phase 1CC

View all 11 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →